Barde C, Thielen A M, Saurat J-H
Clinique et Policlinique de Dermatologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.
Dermatology. 2008;216(2):171-2. doi: 10.1159/000111517. Epub 2008 Jan 23.
In a previous paper we described 2 patients treated with a sequential biologic therapy for chronic plaque psoriasis. We used infliximab as an induction treatment followed by efalizumab. We extended this approach to 3 other patients.
The purpose was to show the feasibility of a sequential approach with biologicals.
Five patients received three infusions of infliximab followed by weekly injections of efalizumab from week 10 on.
The most important findings, summarized in a table, show that none of the patients continued the treatment for more than a year either because of non-responsiveness or because of spontaneous stopping. Moreover, 4 out of 5 patients did not respond or had serious adverse events on reintroduction of infliximab.
Overall, we cannot recommend sequential therapy using infliximab and efalizumab.
在之前的一篇论文中，我们描述了2例接受序贯生物疗法治疗慢性斑块状银屑病的患者。我们使用英夫利昔单抗作为诱导治疗，随后使用依法利珠单抗。我们将这种方法扩展到另外3例患者。
目的是展示生物制剂序贯疗法的可行性。
5例患者接受3次英夫利昔单抗输注，从第10周开始每周注射依法利珠单抗。
总结在表格中的最重要发现表明，由于无反应或自行停药，没有患者持续治疗超过一年。此外，5例患者中有4例在重新使用英夫利昔单抗时无反应或出现严重不良事件。
总体而言，我们不推荐使用英夫利昔单抗和依法利珠单抗的序贯疗法。
